دورية أكاديمية
أعرض في EDS

Melancholic features related to rimonabant.

التفاصيل البيبلوغرافية
العنوان: Melancholic features related to rimonabant.
المؤلفون: de Mattos Viana B; Psychiatry Service, Hospital das Clínicas (HC-UFMG), Federal University of Minas Gerais, Belo Horizonte (MG), Brazil. bernardomviana@yahoo.com, Prais HA, Daker MV
المصدر: General hospital psychiatry [Gen Hosp Psychiatry] 2009 Nov-Dec; Vol. 31 (6), pp. 583-5. Date of Electronic Publication: 2009 Feb 20.
نوع المنشور: Case Reports; Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier/North-Holland Country of Publication: United States NLM ID: 7905527 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-7714 (Electronic) Linking ISSN: 01638343 NLM ISO Abbreviation: Gen Hosp Psychiatry Subsets: MEDLINE
أسماء مطبوعة: Original Publication: New York, Elsevier/North-Holland.
مواضيع طبية MeSH: Appetite Depressants/*adverse effects , Depressive Disorder, Major/*chemically induced , Obesity/*drug therapy , Piperidines/*adverse effects , Pyrazoles/*adverse effects, Adult ; Anti-Anxiety Agents/therapeutic use ; Anxiety Disorders/diagnosis ; Anxiety Disorders/therapy ; Appetite Depressants/therapeutic use ; Clomipramine/therapeutic use ; Depressive Disorder, Major/diagnosis ; Ejaculation/drug effects ; Humans ; Male ; Piperidines/therapeutic use ; Psychotherapy ; Pyrazoles/therapeutic use ; Rimonabant ; Weight Loss/drug effects
مستخلص: Introduction: Obesity is currently considered a global epidemic and its prevention and treatment is a major public health concern, demanding treatment which may combine a sociocultural approach, lifestyle modification, nutritional, pharmacological or surgical strategies. Rimonabant, an endocannabinoid antagonist, has been proposed as an agent for an average weight loss of 4 kg. However, the development of anxiety and depressive symptoms can be major side effects.
Case Report: A 27-year-old businessman, after using rimonabant (20 mg/day) for 1 month for weight loss, developed a major depressive episode with melancholic features, which remitted after the interruption of rimonabant.
Discussion: To our knowledge, a major depressive episode with melancholic or atypical features specifier has not been described since the initiation of rimonabant pharmacological trials. The Hospital Anxiety and Depression Scale, used in the rimonabant trials, assesses several key points of depressive patients. However, it neglects the somatic symptoms that correspond to the additional criterion for both of the mentioned features as well as suicidal ideation. The severity of an episode could also be underestimated depending on the assessment tool or on the clinical interview.
Conclusion: There may be an underestimation of depressive melancholic and atypical side effects related to Rimonabant use, due to the lack of consistent assessment with the appropriate screening tools. Pharmacological strategies should be adjunctive for obesity treatment when there is a failure in the lifestyle and nutritional modification strategies. Moreover, deeper global sociocultural changes should be made in the treatment and control of the global obesity epidemic.
المشرفين على المادة: 0 (Anti-Anxiety Agents)
0 (Appetite Depressants)
0 (Piperidines)
0 (Pyrazoles)
NUV44L116D (Clomipramine)
RML78EN3XE (Rimonabant)
تواريخ الأحداث: Date Created: 20091107 Date Completed: 20100119 Latest Revision: 20181201
رمز التحديث: 20240628
DOI: 10.1016/j.genhosppsych.2008.12.009
PMID: 19892218
قاعدة البيانات: MEDLINE
الوصف
تدمد:1873-7714
DOI:10.1016/j.genhosppsych.2008.12.009